{"id":"NCT02354235","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","officialTitle":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin in Patients With Inadequate Glycemic Control on Teneligliptin)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2016-01","completion":"2016-01","firstPosted":"2015-02-03","resultsPosted":"2018-08-16","lastUpdate":"2018-11-01"},"enrollment":138,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Teneligliptin","otherNames":["Tenelia, MP-513"]},{"type":"DRUG","name":"Canagliflozin","otherNames":["Canaglu, TA-7284"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Canagliflozin + Teneligliptin","type":"EXPERIMENTAL"},{"label":"Placebo + Teneligliptin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.","primaryOutcome":{"measure":"Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)","timeFrame":"Baseline, 24 Weeks","effectByArm":[{"arm":"Canagliflozin+Teneligliptin","deltaMin":-0.97,"sd":0.1},{"arm":"Placebo+Teneligliptin","deltaMin":-0.1,"sd":0.1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":["28177187"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":70},"commonTop":["Nasopharyngitis"]}}